Go Pro
→ Feds Say Your Cash Isn’t Property—Can They Take It? (From Priority Gold) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
InPlay Oil Corp stock logo
AXL
InPlay Oil
C$0.00
C$13.38
▼
C$20.27
N/AN/A2.39 million shs1.80 million shs
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$11.08
-1.2%		$12.07
$9.62
▼
$21.34
$783.89M0.0119,055 shs17,041 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.00%-0.18%-4.35%-12.49%-23.64%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
InPlay Oil Corp stock logo
AXL
InPlay Oil
C$0.00
C$13.38
▼
C$20.27
N/AN/A2.39 million shs1.80 million shs
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$11.08
-1.2%		$12.07
$9.62
▼
$21.34
$783.89M0.0119,055 shs17,041 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.00%-0.18%-4.35%-12.49%-23.64%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
InPlay Oil Corp stock logo
AXL
InPlay Oil
0.00
N/AN/AN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.20
Hold$38.67249.13% Upside

Current Analyst Ratings Breakdown

Latest JOG, PHAR, SAVE, and AXL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/14/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$37.00
8/7/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
8/3/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$37.00 ➝ $38.00
7/31/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
7/30/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
InPlay Oil Corp stock logo
AXL
InPlay Oil
N/AN/AN/AN/AN/AN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$376.13M2.08$0.20 per share55.90$3.95 per share2.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
InPlay Oil Corp stock logo
AXL
InPlay Oil
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$2.85M$0.1292.2936.92N/A2.51%3.40%1.90%11/5/2026 (Estimated)

Latest JOG, PHAR, SAVE, and AXL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2026Q2 2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$0.0630$0.02-$0.0430$0.02$99.52 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
InPlay Oil Corp stock logo
AXL
InPlay Oil
N/AN/AN/AN/AN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
InPlay Oil Corp stock logo
AXL
InPlay Oil
N/AN/AN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.34
3.01
2.31

Institutional Ownership

CompanyInstitutional Ownership
InPlay Oil Corp stock logo
AXL
InPlay Oil
N/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.03%

Insider Ownership

CompanyInsider Ownership
InPlay Oil Corp stock logo
AXL
InPlay Oil
N/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
InPlay Oil Corp stock logo
AXL
InPlay Oil
19,000N/AN/ANot Optionable
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
40770.78 million69.31 millionNot Optionable

Recent News About These Companies

Pharming Group's (PHAR) "Buy" Rating Reiterated at HC Wainwright
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-pharming-groups-phar-buy-rating-reiterated-at-hc-wainwright-2026-09-14/
Pharming Group Obtains US FDA Nod for Rare Primary Immunodeficiency Drug Joenja
September 14 at 4:28 AM  |  marketscreener.comM
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update
September 12 at 9:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-pharming-group-nv-sponsored-adr-nasdaq-phar-short-interest-update-2026-09-12/
Pharming Gets FDA Approval for Joenja to Treat APDS in Children Aged 4-11
September 11 at 6:01 PM  |  marketscreener.comM
Pharming Gets FDA Approval For Joenja In Children With APDS
September 11 at 6:01 PM  |  rttnews.comhttps://www.rttnews.com/3690452/pharming-gets-fda-approval-for-joenja-in-children-with-apds.aspx
FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.
September 11 at 6:01 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/fda-approves-pharming-joenja-first-180000437.html
FDA approves Pharming's Joenja® as first treatment for children with APDS in the U.S.
September 11 at 3:00 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/11/3360484/0/en/fda-approves-pharming-s-joenja-as-first-treatment-for-children-with-apds-in-the-u-s.html
Pharming Group (NASDAQ:PHAR) Shares Gap Down - Time to Sell?
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-pharming-group-nasdaq-phar-shares-gap-down-time-to-sell-2026-09-10/
Pharming: Faltering Rare-Disease Franchise With Two Potentially Transformative Late-Stage Assets
September 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4944187-pharming-faltering-rare-disease-franchise-with-two-potentially-transformative-late-stage-assets
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Consensus Rating of "Hold" by Analysts
September 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31008881
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Consensus Recommendation of "Hold" by Brokerages
September 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-pharming-group-nv-sponsored-adr-nasdaq-phar-given-consensus-recommendation-of-hold-by-brokerages-2026-09-07/
Pharming Group (NASDAQ:PHAR) Shares Gap Up - Should You Buy?
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-pharming-group-nasdaq-phar-shares-gap-up-should-you-buy-2026-09-02/
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Large Increase in Short Interest
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-pharming-group-nv-sponsored-adr-nasdaq-phar-sees-large-increase-in-short-interest-2026-08-27/
Pharming Group (NASDAQ:PHAR) Shares Gap Up - What's Next?
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-pharming-group-nasdaq-phar-shares-gap-up-whats-next-2026-08-26/
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Up 93.0% in July
August 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pharming-group-nv-sponsored-adr-nasdaqphar-short-interest-up-930-in-july-2026-08-16/
Pharming introduces Joenja in Japan for adult and paediatric patients with activated PI3K delta syndrome aged 4 and older
August 14, 2026  |  pharmabiz.comP
Pharming Group N.V.: Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
August 13, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69299602-pharming-group-n-v-pharming-announces-commercial-launch-of-joenja-leniolisib-in-japan-for-adult-and-pediatric-patients-with-apds-aged-4-and-older-399.htm
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
August 13, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/pharming-announces-commercial-launch-of-joenja-leniolisib-in-japan-for-adult-and-pediatric-patients-with-apds-aged-4-and-older-1036452444
Pharming Group (PHAR) Stock Price, Quote, News & History
August 12, 2026  |  benzinga.comhttps://www.benzinga.com/quote/PHAR
Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky
August 7, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/pharming-group-phar-securities-investigation-notice---levi--korsinsky-302845698.html
Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
August 5, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/08/05/10426036.htm

Media Sentiment Over Time

Top Headlines

View All Headlines
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
Illustration of a computer chip on a circuit board with an upward green stock chart line in a server room.
Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
By Thomas Hughes | August 31, 2026
Glass vials, flasks, test tubes, and a microscope in a laboratory setting with scientific analysis equipment.
Insiders Are Betting Big on These 3 Healthcare Stocks
By Thomas Hughes | August 31, 2026
Scientist handles blood sample in lab, symbolizing early cancer detection.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
By Bridget Bennett | September 6, 2026
InPlay Oil stock logo

InPlay Oil TSE:AXL

Arrow Exploration Corp. (operating in Colombia via a branches of its 100% owned subsidiary Arrow Exploration Switzerland GmbH) is a publicly traded company with a portfolio of premier Colombian oil assets that are underexploited, under-explored and offer high potential growth. The Company's business plan is to expand oil production from some of Colombia's most active basins, including the Llanos, Middle Magdalena Valley (MMV) and Putumayo Basin. The asset base is predominantly operated with high working interests, and the Brent-linked light oil pricing exposure combines with low royalties to yield attractive potential operating margins. Pursuant to certain private agreements entered between Arrow and its partner, Arrow is entitled to receive 50% of the production from the Tapir block and has the right to request approval to Ecopetrol S.A. for the assignment of 50% of all rights, interests and obligations under the Tapir Association Contract.

Pharming Group stock logo

Pharming Group NASDAQ:PHAR

$11.08 -0.14 (-1.20%)
As of 12:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas